Advances in Managing High Dose Methotrexate Associated AKI — SSN Webinar

    Dates:
    Organizer:
    Saudi Society of Nephrology & Transplantation (SSN)
    Location:
    Online (Zoom)
    Specialty:
    Nephrology
    Format:
    Online
    CME credits:
    2

    Overview The Saudi Society of Nephrology & Transplantation (SSN) hosts a free evening webinar, Advances in Managing High Dose Methotrexate Associated AKI, on Wednesday 14 October 2026 at 21:00 Riyadh time via Zoom. The session is accredited by the Saudi Commission for Health Specialties (SCFHS) for 2 CME hours and is supported by an educational grant from SERB Pharmaceuticals, with event managemen

    Full details and registration

    Advances in Managing High Dose Methotrexate Associated AKI — SSN Webinar

    Advances in Managing High Dose Methotrexate Associated AKI — SSN Webinar1 / 1

    1 photos · tap to enlarge

    Advances in Managing High Dose Methotrexate Associated AKI — SSN Webinar

    Listed today

    About this event

    Overview

    The Saudi Society of Nephrology & Transplantation (SSN) hosts a free evening webinar, Advances in Managing High Dose Methotrexate Associated AKI, on Wednesday 14 October 2026 at 21:00 Riyadh time via Zoom. The session is accredited by the Saudi Commission for Health Specialties (SCFHS) for 2 CME hours and is supported by an educational grant from SERB Pharmaceuticals, with event management by Event Troop.

    High dose methotrexate (HDMTX) remains a cornerstone of therapy for osteosarcoma, acute lymphoblastic leukaemia, primary CNS lymphoma and other malignancies. Yet acute kidney injury occurs in a meaningful share of courses, driven largely by crystal nephropathy in the renal tubules. Once kidney function falls, methotrexate clearance slows, plasma levels stay toxic for longer, and patients face mucositis, myelosuppression, hepatotoxicity and treatment delays. Recognising and acting on this cycle early is now a core skill in onconephrology.

    What the webinar covers

    • Mechanisms of methotrexate nephrotoxicity and who is at highest risk
    • Prevention: hydration, urine alkalinisation, drug interaction review and monitoring of methotrexate levels
    • Early recognition of delayed clearance and rising creatinine
    • Glucarpidase: indications, timing and evidence for rescue of toxic methotrexate levels
    • Leucovorin rescue, the role of extracorporeal removal, and renal recovery
    • Practical coordination between oncology, nephrology and pharmacy teams

    Faculty

    • Speaker: Shruti Gupta, MD — Consultant Onconephrologist, Harvard Medical School, Boston, USA
    • Moderator: Fahad Alotaibi, MD — Consultant Transplant Nephrologist, King Fahad Specialist Hospital, Dammam, Saudi Arabia

    Dr Gupta is a leading voice in onconephrology, working on kidney complications of cancer therapy, making her talk especially relevant to teams managing chemotherapy in the Kingdom.

    Who should attend

    Nephrologists, oncologists and haematologists, paediatric oncology teams, clinical pharmacists, internal medicine physicians, residents and fellows, and nurses caring for patients receiving high dose chemotherapy.

    Registration

    Registration is free through the official Zoom registration page. SCFHS CME hours (2) are awarded to eligible attendees.

    Ratings & Reviews

    No ratings yet
    2 CME Credits
    Oct 14 – Oct 14, 2026
    Online · Online (Zoom)
    Price TBA
    SCFHS Accredited
    English
    FREE WEEKLY DIGEST

    Never miss a CME event

    Get curated events for your specialty — every week